[go: up one dir, main page]

NO20002133L - Oppløsninger og dispersjoner i fast tilstand av svakt vannoppløselige legemidler - Google Patents

Oppløsninger og dispersjoner i fast tilstand av svakt vannoppløselige legemidler

Info

Publication number
NO20002133L
NO20002133L NO20002133A NO20002133A NO20002133L NO 20002133 L NO20002133 L NO 20002133L NO 20002133 A NO20002133 A NO 20002133A NO 20002133 A NO20002133 A NO 20002133A NO 20002133 L NO20002133 L NO 20002133L
Authority
NO
Norway
Prior art keywords
dispersions
solid state
soluble drugs
state solutions
weakly water
Prior art date
Application number
NO20002133A
Other languages
English (en)
Other versions
NO329755B1 (no
NO20002133D0 (no
Inventor
Siva Narayan Tallavajhala
Xiuying Liu
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20002133L publication Critical patent/NO20002133L/no
Publication of NO20002133D0 publication Critical patent/NO20002133D0/no
Publication of NO329755B1 publication Critical patent/NO329755B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20002133A 1997-10-27 2000-04-26 Farmasoytiske preparater som omfatter en opplosning eller en dispersjon i fast tilstand av en lite vannopploselig, terapeutisk aktiv forbindelse og en eksipiens, samt en fremgangsmate for fremstilling av en eksipiens for et farmasoytisk preparat NO329755B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6333897P 1997-10-27 1997-10-27
PCT/EP1998/006544 WO1999021534A1 (en) 1997-10-27 1998-10-15 Solid state solutions and dispersions of poorly water soluble drugs

Publications (3)

Publication Number Publication Date
NO20002133L true NO20002133L (no) 2000-04-26
NO20002133D0 NO20002133D0 (no) 2000-04-26
NO329755B1 NO329755B1 (no) 2010-12-13

Family

ID=22048528

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002133A NO329755B1 (no) 1997-10-27 2000-04-26 Farmasoytiske preparater som omfatter en opplosning eller en dispersjon i fast tilstand av en lite vannopploselig, terapeutisk aktiv forbindelse og en eksipiens, samt en fremgangsmate for fremstilling av en eksipiens for et farmasoytisk preparat

Country Status (10)

Country Link
EP (1) EP0996429B1 (no)
JP (1) JP2001520984A (no)
CN (1) CN1190187C (no)
AT (1) ATE232087T1 (no)
DE (1) DE69811233T2 (no)
DK (1) DK0996429T3 (no)
ES (1) ES2191977T3 (no)
NO (1) NO329755B1 (no)
PT (1) PT996429E (no)
WO (1) WO1999021534A1 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
EP1082026A1 (en) * 1998-06-05 2001-03-14 Forbes Medi-Tech Inc. Compositions comprising phytosterol and/or phytostanol having enhenced solubility and dispersa
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
SE9901667D0 (sv) * 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
US20010036479A1 (en) * 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
BR0210867A (pt) * 2001-07-06 2004-06-29 Lifecycle Pharma As Processo para a preparação de um material particulado, métodos para aglomeração controlada de um material sólido finamente disperso, para melhorar a biodisponibilidade de uma substância terapêutica e/ou profilaticamente ativa, e para melhorar a vida em prateleira de uma composição farmacêutica, material articulado, composição farmacêutica, uso de um veìculo, material particulado farmacêutico, e, uso de aluminossilicato de magnésio e/ou de aluminometassilicato de magnésio
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
JP2006511525A (ja) * 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
EP1594470A4 (en) * 2003-02-19 2007-10-17 Biovail Lab Int Srl QUICK ABSORPTION 5-HT SELECTIVE AGONIST FORMULATIONS
PT1610822E (pt) 2003-04-02 2011-01-05 Ares Trading Sa Formulações farmacêuticas líquidas ou liofilizadas de fsh e/ou lh em conjunto com o surfactante não iónico poloxâmero 188 e um agente bacteriostático
PL1638595T3 (pl) 2003-06-20 2013-06-28 Ares Trading Sa Liofilizowane formulacje FSH/LH
EP1682092A2 (en) * 2003-11-13 2006-07-26 Alza Corporation Melt blend dispersions comprising a low water solubility drug and an ethylene oxide-propylene oxide block copolymer
EP1701704A2 (en) 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
BRPI0517782A (pt) * 2004-11-17 2008-10-21 Ares Trading Sa formulações de benzotiazol e uso das mesmas
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
ES2277767B1 (es) * 2005-11-04 2008-04-01 Simbec Iberica, S.L. Formas orales solidas de ebastina.
ATE482690T1 (de) * 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
KR101462693B1 (ko) 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP1972336A1 (en) * 2007-03-19 2008-09-24 LEK Pharmaceuticals D.D. Hot-melt micropellets
WO2010143199A1 (en) * 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs
WO2011071194A1 (ko) * 2009-12-08 2011-06-16 주식회사 일화 20-O-β-D-글루코피라노실-20(S)-프로토파낙사디올을 포함하는 고체분산체
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
HUE051133T2 (hu) * 2010-11-01 2021-03-01 Melinta Subsidiary Corp Gyógyászati készítmények
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
NZ741873A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
WO2014176389A1 (en) 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
JP6666840B2 (ja) * 2013-08-01 2020-03-18 エムダブリュ エンキャップ リミテッド 低水溶性薬剤の低融解イオン性塩の組成物および調製方法
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
CN114025744B (zh) * 2019-04-08 2023-10-31 北京科信必成医药科技发展有限公司 改善药物物质溶解的方法及其产品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
JPH05255125A (ja) * 1992-02-29 1993-10-05 Upjohn Co:The 徐放性製剤およびその製法
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
US5487887A (en) * 1993-10-28 1996-01-30 Bristol-Myers Squibb Company Clear antiperspirant roll-on compositions
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
JPH08268878A (ja) * 1995-03-06 1996-10-15 Yoshiyuki Masui 経口医薬品並びに加工食品
US5883103A (en) * 1995-06-07 1999-03-16 Shire Laboratories Inc. Oral acyclovir delivery
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates

Also Published As

Publication number Publication date
DE69811233D1 (de) 2003-03-13
WO1999021534A1 (en) 1999-05-06
ATE232087T1 (de) 2003-02-15
EP0996429B1 (en) 2003-02-05
NO329755B1 (no) 2010-12-13
NO20002133D0 (no) 2000-04-26
CN1190187C (zh) 2005-02-23
EP0996429A1 (en) 2000-05-03
CN1278164A (zh) 2000-12-27
DK0996429T3 (da) 2003-05-26
ES2191977T3 (es) 2003-09-16
PT996429E (pt) 2003-06-30
DE69811233T2 (de) 2003-11-20
JP2001520984A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
NO20002133L (no) Oppløsninger og dispersjoner i fast tilstand av svakt vannoppløselige legemidler
SE0102438D0 (sv) New compounds
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
DE69922676D1 (de) N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
TR200103493T2 (tr) Metaloproteaz önleyicileri
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
GEP20094676B (en) Piperidine compounds and pharmaceutical compositions containing them
GEP20063926B (en) Pharmaceutical compositions of amlodipine and atorvastatin
RU94036448A (ru) Производные галантамина и фармацевтическая композиция
EA200301040A1 (ru) Способ производства фармацевтической композиции низкой дозы
DK1383540T3 (da) Fremgangsmdåer og farmaceutiske sammensætninger til sårheling
SE0102440D0 (sv) New compound
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
WO2003028624A3 (en) Levothyroxine compositions and methods
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
WO2003013441A3 (en) Levothyroxine compositions and methods
SE9902742D0 (sv) New pharmaceutical formultion
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
SE9901340D0 (sv) Novel process

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees